On June 15, 2026, Harbour BioMed Holdings Limited (hereinafter "Harbour BioMed") issued an announcement disclosing the latest ruling in its U.S. patent infringement litigation against Amgen Inc. and its subsidiary Teneobio (together, "Amgen"): a federal jury has found that Amgen willfully infringed on an antibody patent held by Harbour Antibodies, upheld the validity of the patents-in-suit, and decided that Amgen must pay Harbour $20.2 million in damages.

The ruling stems from the patent infringement case filed in 2021 by Harbour Antibodies, entity under the Harbour BioMed umbrella, against Amgen and Teneobio, Inc. in the U.S. District Court for the District of Delaware. The patents-in-suit relate to multiple technologies of Harbour BioMed 's groundbreaking antibody discovery platform, made by Professor Frank Grosveld, a founder of Harbour Antibodies, being considered a pioneering innovation in the field of antibody engineering.

On June 12, 2026, after 5 years of litigation proceedings, the jury in the Delaware federal district court reached a final verdict, finding that the infringement by Amgen was willful, the patents-in-suit is valid, and Harbour is entitled to $20,203,704 in damages—the full amount requested.

The comprehensive victory in this cross-border patent lawsuit against global pharmaceutical giant Amgen breaks the passive and disadvantaged position previously held by Chinese biotech companies in the high-end antibody patent field, proving the solid strength of China's domestic original innovation technologies and the legal enforceability of their patents. This epic victory has become a benchmark case for Chinese pharmaceutical companies in overseas intellectual property rights enforcement.

From IPRdaily

June 15th, 2026